1. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment 
Sanna-Kaisa Herukka, Anja Hviid Simonsen, Niels Andreasen, Ines Baldeiras, Maria Bjerke, Kaj Blennow, Sebastiaan Engelborghs, Giovanni B. Frisoni, Tomasz Gabryelewicz, Samantha Galluzzi, Ron Handels, Milica G. Kramberger, Agnieszka Kulczyńska, Jose Luis Molinuevo, Barbara Mroczko, Agneta Nordberg, Catarina Resende Oliveira, Markus Otto, Juha O. Rinne, Uroš Rot, Esen Saka, Hilkka Soininen, Hanne Struyfs, Silvia Suardi, Pieter Jelle Visser, Bengt Winblad, Henrik Zetterberg, Gunhild Waldemar 
Alzheimer's & Dementia: The Journal of the Alzheimer's Association 
Volume 13, Issue 3, Pages (March 2017)
DOI: /j.jalz
Copyright © 2016 The Authors Terms and Conditions

2. Fig. 1
Decision tree on the recommended use of the cerebrospinal fluid (CSF) biomarkers in diagnostic workup on patients with clinical diagnosis of mild cognitive impairment. *Diagnosis based on medical history, clinical and basic neuropsychological examination, and basic neuroimaging. MCI, mild cognitive impairment; MRI, magnetic resonance imaging; MTA, medial temporal lobe atrophy; AD, Alzheimer's disease; FDG, fluorodeoxyglucose; PET, positron-emission tomography; Aβ, amyloid-β; P-tau, phosphorylated tau.
Alzheimer's & Dementia: The Journal of the Alzheimer's Association  , DOI: ( /j.jalz )
Copyright © 2016 The Authors Terms and Conditions